From scientific evidence to clinical practice: Treatment regimens for macular edema secondary to retinal vein occlusion

M. J. Abraldes, M. A. Zapata, F. Gómez-Ulla, J. García-Arumí

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

Retinal vein occlusion (RVO) is the second most common cause of retinal vascular disease after diabetic retinopathy. Despite the existence of several possible treatment options, none was entirely satisfactory and many patients suffered irreversible visual loss. As a result of the BRAVO, CRUISE and GENEVA trials, ranibizumab and the intravitreal biodegradable implants of dexamethasone has recently been approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of RVO secondary edema. In this paper we begin by describing the current treatment options for RVO associated macular edema and continue with the description of the treatment regimen with ranibizumab. © 2012 Sociedad Española de Oftalmoloǵa. Publicado por Elsevier España, S.L. Todos los derechos reservados.
Original languageEnglish
Pages (from-to)54-62
JournalArchivos de la Sociedad Espanola de Oftalmologia
Volume87
Issue numberSUPPL.1
DOIs
Publication statusPublished - 1 Dec 2012

Keywords

  • Angiography
  • Antiangiogenic drugs
  • Intravitreal implants of dexamethasone
  • Macular edema
  • Photocoagulation
  • Ranibizumab
  • Retinal vein occlusion

Fingerprint Dive into the research topics of 'From scientific evidence to clinical practice: Treatment regimens for macular edema secondary to retinal vein occlusion'. Together they form a unique fingerprint.

Cite this